- Home
- IMTX vs MNKD Comparison
IMTX vs MNKD Comparison
Compare IMTX & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | MNKD |
|---|---|---|
| Founded | N/A | 1991 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | IMTX | MNKD |
|---|---|---|
| Price | $9.00 | $4.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $19.00 | $8.69 |
| AVG Volume (30 Days) | 405.8K | ★ 4.8M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | $25.91 | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $5.05 | $2.23 |
| 52 Week High | $12.41 | $6.51 |
Technical Indicators
Market Signals| Indicator | IMTX | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 53.78 |
| Support Level | $8.62 | $3.78 |
| Resistance Level | $10.67 | $4.15 |
| Average True Range (ATR) | 0.45 | 0.21 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 39.75 | 83.65 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.